Effects of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma and its influence on EOS, IL-4, IgE, TNF-α

中国基层医药 Pub Date : 2020-03-15 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.06.016

Qi Sun, Haijun Yang

{"title":"Effects of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma and its influence on EOS, IL-4, IgE, TNF-α","authors":"Qi Sun, Haijun Yang","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.06.016","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effect of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma, and its influence on eosinophil (EOS), interleukin-4 (IL-4), immunoglobulin E (IgE), tumor necrosis factor-α (TNF-α). \n \n \nMethods \nFrom March 2018 to March 2019, 142 children with asthma admitted to Hangzhou Dajiangdong Hospita were randomly divided into observation group (71 cases) and control group (71 cases) according to the digital table.The patients in the observation group were treated with montelukast sodium tablets combined with pulmicort aerosol, while patients in the control group were treated with pulmicort aerosol.Both two groups were treated for 2 weeks.The levels of EOS, IL-4, IgE and TNF-α, day and night asthma symptom scores and blood gas analysis indicators before and after treatment were compared between the two groups. \n \n \nResults \nThe total effective rate of the observation group (91.55%) was higher than that of the control group (74.65%) (χ2=7.220, P<0.05). After treatment, the scores of asthma symptoms in day[(0.38±0.12)points] and night[(0.42±0.14)points] in the observation group were lower than those in the control group[(0.87±0.19)points and (0.93±0.25)ponts](t=18.373, 14.998, all P<0.05). After treatment, the levels of EOS[(0.38±0.09)×109/L], IL-4[(13.89±3.25)ng/L], IgE[(109.35±16.57)kU/L] and TNF-α[(1.25±0.12)ng/L] in the observation group were lower than those in the control group[(0.73±0.13)×109/L, (18.36±2.70)ng/L, (164.53±23.51)kU/L and (1.49±0.15)ng/L](t=18.652, 8.914, 16.165, 10.528, all P<0.05). \n \n \nConclusion \nMontelukast sodium tablets combined with pulmicort aerosol is effective in the treatment of children with asthma.It can reduce the levels of EOS, IL-4, IgE and TNF-α, alleviate the symptoms of daytime and night asthma. \n \n \nKey words: \nAsthma; Eosinophils; Interleukin-4; Immunoglobulin E; Tumor necrosis factor-a; Montelukast sodium; Pulmicort aerosol; child","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"714-718"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.06.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the effect of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma, and its influence on eosinophil (EOS), interleukin-4 (IL-4), immunoglobulin E (IgE), tumor necrosis factor-α (TNF-α). Methods From March 2018 to March 2019, 142 children with asthma admitted to Hangzhou Dajiangdong Hospita were randomly divided into observation group (71 cases) and control group (71 cases) according to the digital table.The patients in the observation group were treated with montelukast sodium tablets combined with pulmicort aerosol, while patients in the control group were treated with pulmicort aerosol.Both two groups were treated for 2 weeks.The levels of EOS, IL-4, IgE and TNF-α, day and night asthma symptom scores and blood gas analysis indicators before and after treatment were compared between the two groups. Results The total effective rate of the observation group (91.55%) was higher than that of the control group (74.65%) (χ2=7.220, P<0.05). After treatment, the scores of asthma symptoms in day[(0.38±0.12)points] and night[(0.42±0.14)points] in the observation group were lower than those in the control group[(0.87±0.19)points and (0.93±0.25)ponts](t=18.373, 14.998, all P<0.05). After treatment, the levels of EOS[(0.38±0.09)×109/L], IL-4[(13.89±3.25)ng/L], IgE[(109.35±16.57)kU/L] and TNF-α[(1.25±0.12)ng/L] in the observation group were lower than those in the control group[(0.73±0.13)×109/L, (18.36±2.70)ng/L, (164.53±23.51)kU/L and (1.49±0.15)ng/L](t=18.652, 8.914, 16.165, 10.528, all P<0.05). Conclusion Montelukast sodium tablets combined with pulmicort aerosol is effective in the treatment of children with asthma.It can reduce the levels of EOS, IL-4, IgE and TNF-α, alleviate the symptoms of daytime and night asthma. Key words: Asthma; Eosinophils; Interleukin-4; Immunoglobulin E; Tumor necrosis factor-a; Montelukast sodium; Pulmicort aerosol; child

查看原文本刊更多论文

孟鲁司特钠片联合普米克气雾剂治疗儿童哮喘及其对EOS、IL-4、IgE、TNF-α的影响

目的探讨孟鲁司特钠片联合普米克气雾剂治疗儿童哮喘的疗效及其对嗜酸性粒细胞（EOS）、白细胞介素-4（IL-4）、免疫球蛋白E（IgE）、肿瘤坏死因子-α（TNF-α）的影响。方法自2018年3月至2019年3月，将杭州大江东医院收治的142例哮喘患儿按数字表随机分为观察组71例和对照组71例。观察组采用孟鲁司特钠片联合普米克气雾剂治疗，对照组采用普米克气溶胶治疗。两组均治疗2周。比较两组治疗前后EOS、IL-4、IgE、TNF-α水平、昼夜哮喘症状积分及血气分析指标。结果观察组总有效率（91.55%）高于对照组（74.65%）（χ2=7.220，P<0.05）。治疗后，观察组哮喘症状白天[（0.38±0.12）分]和夜间[（0.42±0.14）分]评分均低于对照组[（0.87±0.19）分和（0.93±0.25）分]（t=18.373，14.998，均P<0.05），109/L]、IL-4[（13.89±3.25）ng/L]、，观察组IgE[（109.35±16.57）kU/L]和TNF-α[（1.25±0.12）ng/L]均低于对照组[（0.73±0.13）×109/L、（18.36±2.70）ng/L、（164.53±23.51）kU/L和（1.49±0.15）ng/L]（t=18.652、8.914、16.165、10.528，均P<0.05）。可降低EOS、IL-4、IgE和TNF-α水平，缓解昼夜哮喘症状。关键词：哮喘；嗜酸性粒细胞；白细胞介素-4；免疫球蛋白E；肿瘤坏死因子-a；孟鲁司特钠；普米克气雾剂；儿童

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.